Brand product · Tirzepatide
Zepbound: FDA Status, Uses, Safety and Cost
Two receptor targets (GIP + GLP-1)
What Zepbound is
Zepbound is Eli Lilly’s brand of tirzepatide approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication FDA approved for OSA. It contains the same active ingredient as Mounjaro, which is approved for type 2 diabetes.
Key facts
| Generic (active ingredient) | Tirzepatide |
|---|---|
| Brand names | Zepbound |
| Drug class | Dual GIP and GLP-1 receptor agonist |
| Manufacturer | Eli Lilly and Company |
| FDA status | FDA ApprovedApproved for chronic weight management |
| Administration | Subcutaneous injection (prefilled pen or single-dose vial) |
| Frequency | Once weekly |
| Approval date | November 2023 (weight management); December 2024 (obstructive sleep apnea) |
| Prescription required | Yes |
| Official label | Prescribing information (DailyMed) |
What Zepbound is approved for
- Chronic weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity
- Moderate-to-severe obstructive sleep apnea in adults with obesity
How Zepbound works
Tirzepatide activates both GIP and GLP-1 hormone receptors, reducing appetite and calorie intake and slowing gastric emptying.
- 1
Medication binds
A GLP-1 receptor agonist activates the receptor for the natural GLP-1 hormone.
- 2
Signals are sent
Appetite-regulating areas of the brain are affected, increasing fullness.
- 3
Stomach slows
Gastric emptying slows, so food stays in the stomach longer.
- 4
Intake falls
Per FDA labeling, weight reduction happens mainly through eating fewer calories.
Administration
Zepbound is given by subcutaneous injection (prefilled pen or single-dose vial), once weekly.
We do not publish dosing guidance
Dose selection, titration schedules, and what to do about a missed dose are individual clinical decisions. Follow the instructions from your prescriber and the official prescribing information — never a website.
Important safety information
Boxed Warning — the FDA’s most serious warning
Risk of thyroid C-cell tumors: caused thyroid C-cell tumors in rodents at clinically relevant exposures; it is unknown whether this occurs in humans. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Summarized from the product’s FDA prescribing information. Read the full label, linked in Sources below.
Contraindications (who should not take it)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or product components
Summarized from the FDA prescribing information. This is not the complete list — see the full label.
Common adverse reactions from official labeling
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Dyspepsia (indigestion)
- Injection site reactions
- Fatigue
- Hypersensitivity reactions
- Belching (eructation)
- Hair loss
- GERD
The most common adverse reactions listed in the product’s FDA prescribing information. Frequency and full adverse-reaction data are in the label.
Brand and generic relationships
Zepbound is a brand product containing the active ingredient tirzepatide.
Cost and access
- Prescription only.
- Eli Lilly offers a Zepbound savings card for eligible commercially insured patients, and sells certain single-dose vial strengths through the LillyDirect self-pay pharmacy channel — current prices and terms are on the official Lilly sites.
- Only buy through state-licensed pharmacies; the FDA has warned about compounded and counterfeit tirzepatide products.
Why we don't publish a price
List prices, savings-card amounts, and self-pay offers change frequently and vary by pharmacy, plan, and location. Any figure we printed would be wrong for many readers and stale within weeks. See our cost guide for how to get an accurate number for your own situation.
Insurance considerations
- Commercial coverage varies by employer plan; prior authorization is common.
- The obstructive sleep apnea indication may open coverage paths (including Medicare consideration) that the weight-management indication alone would not — coverage rules are plan-specific and evolving.
More detail: how insurance coverage works for weight-loss medication.
Comparisons
Frequently asked questions
- Is Zepbound the same as Mounjaro?
- Both are tirzepatide made by Eli Lilly. Zepbound is approved for chronic weight management and obstructive sleep apnea; Mounjaro is approved for type 2 diabetes. See our Mounjaro vs. Zepbound comparison.
- Is there a generic Zepbound?
- No. There is no FDA-approved generic tirzepatide, and compounded tirzepatide is not an FDA-approved product.
- Is Zepbound approved for sleep apnea?
- Yes. In December 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
Related guides
Sources
- Zepbound prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
- Drugs@FDA database — FDA. Link last verified August 12, 2026.
- Zepbound official site (Eli Lilly) — Manufacturer. Link last verified August 12, 2026.
Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.